Plasmapheresis in TTP Mimics: When Are We Getting It Wrong? Check back later for a possible video summary. Videos are created for most articles. Introduction Plasmapheresis has revolutionized the treatment of thrombotic thrombocytopenic purpura (TTP), reducing mortality rates from nearly 100% to less than 10–20%. Despite this progress, diagnostic uncertainty remains a
Hematology
Monoclonal Antibodies in Relapsed Multiple Myeloma: The Era of Bispecifics and Beyond
Monoclonal Antibodies in Relapsed Multiple Myeloma: The Era of Bispecifics and Beyond Check back later for a possible video summary. Videos are created for most articles. Abstract This paper provides an in-depth review of monoclonal antibody (mAb) therapies in the treatment of relapsed multiple myeloma (MM), with a particular focus on bispecific antibodies
Thrombocytopenia in the ICU: Essential Guide for Clinical Hematologists
Thrombocytopenia in the ICU: Essential Guide for Clinical Hematologists Please like and subscribe if you enjoyed this video :-) Introduction Thrombocytopenia is a frequent hematologic abnormality in critically ill patients, affecting up to 67.6% at ICU admission, with an additional 14–44% developing it during their stay.
Hidden Signs of GATA2 Deficiency: Why Doctors Miss This Rare Disorder
Hidden Signs of GATA2 Deficiency: Why Doctors Miss This Rare Disorder Check back later for a possible video summary. Videos are created for most articles. Introduction GATA2 deficiency is the most common hereditary predisposition to pediatric myelodysplastic syndrome (MDS), yet it remains one of the most frequently overlooked genetic disorders in clinical practice. This
Is Clonal Hematopoiesis a New Cardiovascular Risk Factor?
Is Clonal Hematopoiesis a New Cardiovascular Risk Factor? Check back later for a possible video summary. Videos are created for most articles. Abstract This paper explores growing evidence that links clonal hematopoiesis, particularly clonal hematopoiesis of indeterminate potential (CHIP), to an increased risk of
New Anticoagulants vs LMWH in Cancer-Associated Thrombosis: Latest Evidence
New Anticoagulants vs LMWH in Cancer-Associated Thrombosis: Latest Evidence Please like and subscribe if you enjoyed this video :-) Introduction Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, remains one of the most common and life-threatening complications in patients with cancer.
JAK2, CALR, and MPL Mutations: Advanced Treatment Strategies That Work
AI Blood Cancer Detection: 92% Accuracy in New Clinical Study
From COVID to Cancer: Understanding Hypercoagulability in Modern Practice – How Coagulopathies Evolved During the Pandemic
The Mystery of the Low Platelet Count: When is it ITP, and When is it Not? – Diagnostic pearls and Red flags for Thrombocytopenia
